Skip Navigation

Fidaxomicin Film Coated Tablets added to Adalvo Product Portfolio

20 September 2022

Adalvo is pleased to announce the addition of Fidaxomicin Film Coated Tablets, to our Product Portfolio within the antibiotic line.

Our product is being developed in collaboration with one of our strategic partners, based on the reference brand DIFICLIR. The product is indicated in the treatment of Clostridioides Difficile Infections (CDI). The brand sold approximately $239mio globally in 2021, having a significant growth potential with Global 3Y CAGR at 14%, according to IQVIA.

Due to the challenging clinical program, Fidaxomicin is a difficult-to-make antibiotic product in a highly growing segment. This further enhances our capabilities and due to its challenging nature, showcases our ability to bring complex products to our partners, with a competitive approach and early launch opportunities. In this respect, we expect Adalvo to be amongst the first wave of filers and we expect to launch the product on day-1.

Adalvo is working on several interesting antibiotic and antimycotic projects, as depicted below and we will continue to expand our offerings within this domain, continuously.

Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force